If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJohnson Matthey Regulatory News (JMAT)

Share Price Information for Johnson Matthey (JMAT)

Share Price is delayed by 15 minutes
Get Live Data
1,919.00    -9.00 (-0.47%)
Bid:
1,902.00
Ask:
1,911.00
Spread: 9.00 (0.473%)
Market Cap: £3.22b
JMAT Live PriceLast checked at - London Stock Exchange

Intraday Johnson Matthey Share Chart

Update on Catalyst Technologies sale

23 Feb 2026 07:00

RNS Number : 9927T
Johnson Matthey PLC
23 February 2026
 

23rd February 2026

 

Johnson Matthey Plc

(the Company)

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

Transaction update

On 22nd May 2025, Johnson Matthey Plc ("JM") and Honeywell International, Inc. ("Honeywell") announced an agreement to sell JM's Catalyst Technologies business ("CT") to Honeywell (the "Transaction").

JM and Honeywell have agreed to extend the long stop date for satisfaction of the closing conditions (the "Long Stop Date") from 21st February to 21st July 2026. In the event that the only remaining antitrust approval condition is not satisfied by the Long Stop Date, the Long Stop Date may be further extended to 21st August 2026, if certain conditions are met. JM and Honeywell expect to complete the Transaction by the end of August 2026.

In agreeing to extend the Long Stop Date, JM and Honeywell have also agreed to amend the financial terms of the Transaction to reflect CT's business performance during 2025/26, which includes the deferral of key sustainable solutions licensing projects and reduced profitability from the supply of catalysts due to the challenging market environment. Accordingly, JM has agreed to sell the CT business to Honeywell for an enterprise value of £1,325 million on a cash and debt-free basis.

Consequently, JM now expects to return c.£1,000 million of net sale proceeds to its shareholders following completion of the Transaction, comprising £800 million through a special dividend with share consolidation, and £200 million through an on-market share buyback programme.

JM continues to make good progress on the implementation of its new cash-focused business model and is on track to deliver 2025/26 performance in line with guidance. This includes group underlying operating profit growth at the higher end of a mid single digit percentage range¹, and positive free cash flow that is materially higher than last year².

The person responsible for the release of this announcement is Simon Price, General Counsel and Company Secretary of JM.

ENDS

 

Enquiries: 

Investor Relations

 

 

Louise Curran

Head of Investor Relations

+44 20 7269 8235

Media

Sinead Keller

Guy Bates 

Group External Relations Director

Kekst CNC

+44 20 7269 8218

+44 7581 056 415

 

Johnson Matthey Plc is listed on the London Stock Exchange (JMAT)

Registered in England & Wales number: 00033774Legal Entity Identifier number: 2138001AVBSD1HSC6Z10

 

Notes:

1.

Underlying operating profit is on a pro forma basis excluding CT and Value Businesses, and at constant precious metal prices and constant currency. 

2.

Free cash flow defined as net cash flow from operating activities (excluding disposal related costs) after net interest paid, net purchases of non-current assets and investments and the principal elements of lease payments, adjusted to reflect the classification of Catalyst Technologies as a discontinued operation. 2024/25: £64 million inflow.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURXLLLLQLLEBBF
Date   Source Headline
2nd Jul 20243:04 pmRNSHolding(s) in Company
1st Jul 20242:38 pmRNSCompletion of Medical Device Components sale
1st Jul 20247:00 amRNSDirectorate Change
27th Jun 20245:54 pmRNSHolding(s) in Company
27th Jun 202412:03 pmRNSHolding(s) in Company
27th Jun 20247:00 amRNSJohnson Matthey: PGM Services seminar
25th Jun 202410:35 amRNSHolding(s) in Company
20th Jun 202412:24 pmRNSDirector/PDMR Shareholding
14th Jun 20243:00 pmRNSHolding(s) in Company
6th Jun 20249:00 amRNSAnnual Financial Report
28th May 202410:13 amRNSHolding(s) in Company
23rd May 20247:00 amRNSJohnson Matthey Full Year Results
21st May 20245:04 pmRNSHolding(s) in Company
20th May 20245:04 pmRNSHolding(s) in Company
16th May 20244:43 pmRNSDirector/PDMR Shareholding
16th May 20244:11 pmRNSHolding(s) in Company
14th May 202412:05 pmRNSHolding(s) in Company
3rd May 20243:31 pmRNSHolding(s) in Company
2nd May 20249:00 amRNSHolding(s) in Company
22nd Apr 20243:39 pmRNSHolding(s) in Company
18th Apr 20245:33 pmRNSDirector/PDMR Shareholding
17th Apr 20243:07 pmRNSHolding(s) in Company
10th Apr 20243:10 pmRNSHolding(s) in Company
10th Apr 20249:47 amRNSHolding(s) in Company
9th Apr 20249:00 amRNSHolding(s) in Company
8th Apr 20249:00 amRNSHolding(s) in Company
3rd Apr 20245:16 pmRNSHolding(s) in Company
2nd Apr 20249:01 amRNSHolding(s) in Company
2nd Apr 20249:00 amRNSHolding(s) in Company
27th Mar 20241:46 pmRNSHolding(s) in Company
22nd Mar 20243:11 pmRNSHolding(s) in Company
21st Mar 202412:13 pmRNSDirector/PDMR Shareholding
20th Mar 20247:00 amRNSJohnson Matthey sale of Medical Device Components
18th Mar 20243:05 pmRNSHolding(s) in Company
18th Mar 20242:32 pmRNSHolding(s) in Company
12th Mar 20245:12 pmRNSHolding(s) in Company
12th Mar 20249:00 amRNSHolding(s) in Company
11th Mar 20249:00 amRNSHolding(s) in Company
7th Mar 20244:20 pmRNSHolding(s) in Company
22nd Feb 20244:53 pmRNSDirector/PDMR Shareholding
20th Feb 20243:57 pmRNSHolding(s) in Company
19th Feb 20243:12 pmRNSHolding(s) in Company
15th Feb 20249:54 amRNSDirector/PDMR Shareholding
9th Feb 20244:17 pmRNSHolding(s) in Company
9th Feb 202412:31 pmRNSDirector/PDMR Shareholding
8th Feb 20242:17 pmRNSHolding(s) in Company
1st Feb 20244:08 pmRNSHolding(s) in Company
29th Jan 20243:22 pmRNSHolding(s) in Company
29th Jan 20242:37 pmRNSHolding(s) in Company
29th Jan 20242:35 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.